Implications of Tamoxifen Resistance in Palbociclib Efficacy for Patients with Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: Subgroup Analyses of KCSG-BR15-10 (YoungPEARL)

PURPOSE: YoungPEARL (KCSG-BR15-10) trial demonstrated a significant progression-free survival (PFS) benefit for premenopausal patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2−) metastatic breast cancer (MBC) for palbociclib plus exemestane with ovar...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Cancer Res Treat
Главные авторы: Lee, Jiyun, Im, Seock-Ah, Kim, Gun Min, Jung, Kyung Hae, Kang, Seok Yun, Park, In Hae, Kim, Jee Hyun, Ahn, Hee Kyung, Park, Yeon Hee
Формат: Artigo
Язык:Inglês
Опубликовано: Korean Cancer Association 2021
Предметы:
Original Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC8291192/
https://ncbi.nlm.nih.gov/pubmed/33332933
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4143/crt.2020.1246
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы